Pharming Group (NASDAQ:PHAR) Shares Gap Down to $8.27

Pharming Group (NASDAQ:PHAR) shares gapped down prior to trading on Tuesday . The stock had previously closed at $8.27, but opened at $8.02. Pharming Group shares last traded at $8.02, with a volume of 982 shares changing hands.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and issued a $37.00 price target on shares of Pharming Group in a research note on Friday, May 31st.

Pharming Group Stock Up 4.8 %

The stock’s 50 day moving average is $9.08 and its 200 day moving average is $10.68.

Pharming Group (NASDAQ:PHAR) last posted its quarterly earnings data on Wednesday, May 8th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.20). The business had revenue of $55.59 million during the quarter, compared to the consensus estimate of $68.43 million. Pharming Group had a negative net margin of 4.01% and a negative return on equity of 4.61%. Equities analysts forecast that Pharming Group will post -0.03 earnings per share for the current year.

Institutional Trading of Pharming Group

A hedge fund recently bought a new stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC purchased a new position in shares of Pharming Group (NASDAQ:PHAR) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 17,710 shares of the company’s stock, valued at approximately $202,000. 0.03% of the stock is owned by institutional investors and hedge funds.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.